Department of Nephrology and Medical Intensive Care, Charité University Medicine Berlin, Charitéplatz 1, 10117, Berlin, Germany.
Department of Microbiology, Labor Berlin GmbH, Berlin, Germany.
World J Urol. 2019 May;37(5):957-967. doi: 10.1007/s00345-018-2440-2. Epub 2018 Aug 14.
Perioperative antibiotic prophylaxis (PAP) is an integral part of kidney transplantation to prevent surgical site infections (SSI). In July 2015, we changed our standard from a multiple-dose to a single-dose (SD) prophylaxis. Here, we report on results with both regimens and a related survey among Eurotransplant renal transplantation centers.
From July 2015, all kidney graft recipients of our center were scheduled to receive SD i.v. cefazolin (group SD, n = 107). They were compared to patients, transplanted since January 2014, receiving our previous standard (i.v. piperacillin/flucloxacillin) until postoperative day (POD) 7, plus oral sultamicillin until POD 10 (group MD, n = 105). The primary endpoint was the number of SSIs during a 3-month observational period.
The frequency of SSI episodes was generally low (group SD vs. MD: 2 vs. 4, p = 0.40). Of note, urinary tract infections occurred in 40 SD vs. 36 MD patients, respectively (p = 0.60). Urinary tract infections were caused by Escherichia coli in 36.8%. Female gender was the only independent risk factor on multivariate analysis (p = 0.002). In addition, 12 episodes of urosepsis in both groups occurred. All-cause infection with multi-resistant bacteria occurred less frequently in SD vs. MD patients (3.7% vs. 8.6%, p = 0.16). A majority of Eurotransplant centers used i.v. single-dose cephalosporins (36.9%), although substances and duration varied remarkably.
Single-dose cefazolin was equally effective and less expensive compared to our previous MD regimen. Based on these findings, we conclude that future prospective studies should be designed to confirm the non-inferiority of single-dose antibiotic regimens.
围手术期抗生素预防(PAP)是肾移植的一个重要组成部分,以预防手术部位感染(SSI)。2015 年 7 月,我们将标准方案从多剂量方案改为单剂量(SD)方案。在此,我们报告两种方案的结果,并报告 Eurotransplant 肾移植中心的相关调查。
从 2015 年 7 月开始,我们中心的所有肾移植受者都计划接受 SD 静脉注射头孢唑林(SD 组,n=107)。他们与自 2014 年 1 月以来接受我们以前标准方案(静脉注射哌拉西林/他唑巴坦)至术后第 7 天,加用口服舒他西林至术后第 10 天的患者(MD 组,n=105)进行比较。主要终点是 3 个月观察期内 SSI 的发生数量。
SSI 发作的频率通常较低(SD 组与 MD 组:2 与 4,p=0.40)。值得注意的是,SD 组和 MD 组分别有 40 例和 36 例发生尿路感染(p=0.60)。尿路感染由大肠杆菌引起的占 36.8%。多变量分析显示,女性是唯一的独立危险因素(p=0.002)。此外,两组各有 12 例尿脓毒症。SD 组与 MD 组的全因感染耐药菌的发生率较低(3.7%与 8.6%,p=0.16)。
与我们以前的 MD 方案相比,单剂量头孢唑林同样有效且成本更低。基于这些发现,我们得出结论,未来应设计前瞻性研究来证实单剂量抗生素方案的非劣效性。